Phenotypic screening-the fast track to novel antibody discovery

Ralph R Minter; Alan M Sandercock; Steven J Rust

doi:10.1016/j.ddtec.2017.03.004

Phenotypic screening-the fast track to novel antibody discovery

Drug Discov Today Technol. 2017 Mar:23:83-90. doi: 10.1016/j.ddtec.2017.03.004. Epub 2017 Apr 25.

Authors

Ralph R Minter¹, Alan M Sandercock¹, Steven J Rust²

Affiliations

¹ Department of Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK.
² Department of Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK. Electronic address: rusts@medimmune.com.

PMID: 28647091
DOI: 10.1016/j.ddtec.2017.03.004

Abstract

The majority of antibody therapeutics have been isolated from target-led drug discovery, where many years of target research preceded drug program initiation. However, as the search for validated targets becomes more challenging and target space becomes increasingly competitive, alternative strategies, such as phenotypic drug discovery, are gaining favour. This review highlights successful examples of antibody phenotypic screens that have led to clinical drug candidates. We also review the requirements for performing an effective antibody phenotypic screen, including antibody enrichment and target identification strategies. Finally, the future impact of phenotypic drug discovery on antibody drug pipelines will be discussed.

Publication types

Review

MeSH terms

Antibodies / chemistry*
Drug Discovery
Drug Evaluation, Preclinical
Humans

Substances

Antibodies